TC BioPharm: Funding, Investors & Team (Oct 2026)
TC BioPharm's central goal is to create and market inventive cell-based items to treat infection, working on quiet wellbeing and Quality of Life. TC BioPharm is a clinical improvement organization with a cell-based item pipeline equipped for treating various problems including malignant growth and serious viral diseases. TCB is right now directing Phase II/III clinical investigations of its lead item, ImmuniCell®, in renal cell cancinoma, non-little cell cellular breakdown in the lungs and melanoma patients.
TC BioPharm has raised $4.0M across 1 funding round on record, the most recent a Post-IPO Equity of $4.0M announced in Jun 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TC BioPharm Company Profile and Key Stats
Latest funding round on record: Jun 2022.
TC BioPharm Funding Rounds
TC BioPharm Founders and Leadership Team
No contact details are on record for this team yet.
TC BioPharm Funding Compared to Other Biotechnology Startups
TC BioPharm's latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TC BioPharm in Biotechnology and Holytown
Companies Similar to TC BioPharm
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
TC BioPharm Funding FAQs
What does TC BioPharm do?
TC BioPharm's central goal is to create and market inventive cell-based items to treat infection, working on quiet wellbeing and Quality of Life. TC BioPharm is a clinical improvement organization with a cell-based item pipeline equipped for treating various problems including malignant growth and serious viral diseases. TCB is right now directing Phase II/III clinical investigations of its lead item, ImmuniCell®, in renal cell cancinoma, non-little cell cellular breakdown in the lungs and melanoma patients.
How much funding has TC BioPharm raised?
TC BioPharm has raised $4.0M across 1 round on record. The most recent is a Post-IPO Equity of $4.0M announced in Jun 2022.
When did TC BioPharm last raise funding?
TC BioPharm's most recent funding round on record is a Post-IPO Equity of $4.0M, announced in Jun 2022.
Who founded TC BioPharm?
FundedIQ lists Michael Leek (Founder) at TC BioPharm.
Where is TC BioPharm headquartered?
TC BioPharm is based in Holytown, North Lanarkshire, United Kingdom.
How many employees does TC BioPharm have?
TC BioPharm is in the 51-100 employee band.
How does TC BioPharm's funding compare to other Biotechnology startups?
TC BioPharm's latest round of $4.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's TC BioPharm Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TC BioPharm is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.